Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00316706
Registration number
NCT00316706
Ethics application status
Date submitted
19/04/2006
Date registered
21/04/2006
Date last updated
18/09/2012
Titles & IDs
Public title
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
Query!
Scientific title
A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013
Query!
Secondary ID [1]
0
0
104902
Query!
Secondary ID [2]
0
0
104896 (month 18 FU)
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cervical Intraepithelial Neoplasia
0
0
Query!
Papillomavirus Infection
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)
Other interventions - Havrix™
Experimental: Cervarix Group - Subjects received 3 doses of GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) during the primary study (NCT00196924). Subjects from this group continued the long-term follow-up study until Month 48.
Active Comparator: Havrix Group - Subjects received 3 doses of Havrix™ (hepatitis A vaccine [HAV]) during the primary study (NCT00196924). Subjects from the this group completed the study at Month 24.
Other interventions: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)
Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule
Other interventions: Havrix™
Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies
Query!
Assessment method [1]
0
0
Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).
Query!
Timepoint [1]
0
0
At 18, 24, 36 and 48 months
Query!
Secondary outcome [1]
0
0
Titers of Anti-3-O-desacyl-4'-Monophosphoryl Lipid A (Anti-MPL) Antibodies During the Initial 2 Years Follow-up
Query!
Assessment method [1]
0
0
Titers are given as Geometric Mean Titers (GMTs) expressed as EL.U/mL.
Query!
Timepoint [1]
0
0
At Months 18 and 24
Query!
Secondary outcome [2]
0
0
Titers of Anti-3-O-desacyl 4'-Monophosphoryl Lipid A (Anti-MPL) Antibodies During the Last 2 Years Follow-up
Query!
Assessment method [2]
0
0
Titers are given as Geometric Mean Titers (GMTs) expressed as EL.U/mL.
Query!
Timepoint [2]
0
0
At Month 36 and 48
Query!
Secondary outcome [3]
0
0
Number of Subjects Reporting Pregnancies, Serious Adverse Events (SAEs), New Onset Chronic Diseases (NOCDs), and Conditions Prompting Emergency Room (ER) Visits or Physician Visits That Are Not Related to Common Diseases During the First 2 Years Follow-up
Query!
Assessment method [3]
0
0
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
New onset of chronic diseases (NOCDs) assessed include e.g. autoimmune disorders, asthma, type I diabetes.
Query!
Timepoint [3]
0
0
From Month 18 to Month 24
Query!
Secondary outcome [4]
0
0
Number of Subjects Reporting Pregnancies, Serious Adverse Events (SAEs), New Onset Chronic Diseases (NOCDs), and Conditions Prompting Emergency Room During the Last 2 Years Follow-up
Query!
Assessment method [4]
0
0
Serious adverse events assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
New onset of chronic diseases (NOCDs) assessed include e.g. autoimmune disorders, asthma, type I diabetes.
Query!
Timepoint [4]
0
0
From Month 24 to Month 48
Query!
Eligibility
Key inclusion criteria
- A female who enrolled in the immunological subset of the 580299-013 study, received
the three doses of vaccine/control according to the treatment allocation and completed
the 580299-013 study.
- Written informed assent obtained from the subject and written informed consent
obtained from a parent or legally acceptable representative of the subject.
Query!
Minimum age
10
Years
Query!
Query!
Maximum age
14
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- Concurrently participating in another clinical study, at any time during the study
period, in which the subject has been or will be exposed to an investigational or a
non-investigational product (pharmaceutical product or device).
- Use of any investigational or non-registered product (drug or vaccine) or planned use
during the study period.
- Chronic administration of immunosuppressants or other immune-modifying drugs occurring
less than 3 months prior to blood sampling.
- Administration of immunoglobulins and/or any blood products within the 3 months
preceding blood sampling.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/01/2009
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1245
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
Colombia
Query!
State/province [1]
0
0
Bogota
Query!
Country [2]
0
0
Germany
Query!
State/province [2]
0
0
Baden-Wuerttemberg
Query!
Country [3]
0
0
Germany
Query!
State/province [3]
0
0
Bayern
Query!
Country [4]
0
0
Germany
Query!
State/province [4]
0
0
Mecklenburg-Vorpommern
Query!
Country [5]
0
0
Germany
Query!
State/province [5]
0
0
Niedersachsen
Query!
Country [6]
0
0
Germany
Query!
State/province [6]
0
0
Nordrhein-Westfalen
Query!
Country [7]
0
0
Germany
Query!
State/province [7]
0
0
Rheinland-Pfalz
Query!
Country [8]
0
0
Germany
Query!
State/province [8]
0
0
Schleswig-Holstein
Query!
Country [9]
0
0
Germany
Query!
State/province [9]
0
0
Thueringen
Query!
Country [10]
0
0
Germany
Query!
State/province [10]
0
0
Berlin
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Hamburg
Query!
Country [12]
0
0
Honduras
Query!
State/province [12]
0
0
Comayaguela
Query!
Country [13]
0
0
Panama
Query!
State/province [13]
0
0
Panamá
Query!
Country [14]
0
0
Taiwan
Query!
State/province [14]
0
0
Taipei
Query!
Country [15]
0
0
Taiwan
Query!
State/province [15]
0
0
Tao Yuan County
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This protocol posting deals with objectives & outcome measures of the extension phase up to
Month 48. The objective of the extension study is to evaluate the long-term immunogenicity of
the HPV 16/18 L1 VLP AS04 vaccine (for all subjects in the HPV Vaccine Group) by
enzyme-linked immunosorbent assay (ELISA). The objectives & outcome measures of the primary
phase are presented in a separate protocol posting (NCT00196924).
The long-term follow-up study will be blinded until the primary study is unblinded and will
be open for all visits subsequent to unblinding of primary study HPV-013 (NCT00196924).
During the open phase, only subjects who received the HPV-16/18 VLP/AS04 vaccine during the
primary study will continue their participation in the follow-up study until Month 48.
Subjects in the Control group (Havrix®) will attend one further visit as their last study
visit.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
2007.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00316706
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00316706
Download to PDF